Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AdAlta Ltd. ( (AU:1AD) ) has provided an announcement.
AdAlta has secured a Canadian composition of matter patent for its first-in-class anti-fibrotic biologic AD-214, extending protection for the drug’s core i‑body sequence, related variants, and pharmaceutical formulations to 2036. This grant completes a portfolio of composition of matter patents for AD-214 across major commercial markets, including the U.S., European Union, Japan and Canada, as well as key potential manufacturing bases such as India and China.
The expanded patent coverage strengthens AdAlta’s intellectual property position around AD-214 in key indications such as idiopathic pulmonary fibrosis and kidney fibrosis, enhancing the asset’s appeal for partnering following positive Phase I data. The company has also filed additional dosing and method-of-treatment patent applications that, if successful, could further extend AD-214’s protection to 2043, reinforcing its strategic positioning in the competitive market for anti-fibrotic therapies.
The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Limited is a clinical-stage biotechnology company focused on developing next-generation cell and protein therapeutics, with a particular emphasis on cellular immunotherapies for solid cancers and novel biologics for fibrotic and infectious diseases. Through its AdCella subsidiary, the company pursues an “East to West” model, in-licensing differentiated T cell therapies from Asian innovators and advancing them through FDA-regulated manufacturing and early-stage trials for eventual out-licensing to larger biopharmaceutical partners.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$8.92M
Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.